ANI Pharmaceuticals Inc - Asset Resilience Ratio
ANI Pharmaceuticals Inc (ANIP) has an Asset Resilience Ratio of 0.63% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of ANI Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how ANI Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See ANI Pharmaceuticals Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ANI Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ANIP company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.13 Million | 0.63% |
| Total Liquid Assets | $9.13 Million | 0.63% |
Asset Resilience Insights
- Limited Liquidity: ANI Pharmaceuticals Inc maintains only 0.63% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ANI Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare ANI Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Cipla Limited
NSE:CIPLA |
Drug Manufacturers - Specialty & Generic | 20.75% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.92% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 11.00% |
Annual Asset Resilience Ratio for ANI Pharmaceuticals Inc (2004–2025)
The table below shows the annual Asset Resilience Ratio data for ANI Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.63% | $9.13 Million | $1.44 Billion | +0.14pp |
| 2024-12-31 | 0.49% | $6.31 Million | $1.28 Billion | -- |
| 2023-12-31 | 0.00% | $0.00 | $904.42 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $412.14 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $322.86 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $285.26 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $263.71 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $44.50 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $38.77 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $62.38 Million | -- |
| 2008-12-31 | 17.12% | $3.03 Million | $17.68 Million | -30.91pp |
| 2007-12-31 | 48.03% | $15.01 Million | $31.24 Million | +31.06pp |
| 2006-12-31 | 16.97% | $3.80 Million | $22.37 Million | -74.85pp |
| 2005-12-31 | 91.82% | $8.79 Million | $9.57 Million | +1.51pp |
| 2004-12-31 | 90.30% | $16.10 Million | $17.83 Million | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more